Chelsie Derman

2 weeks ago | hcplive.com | Chelsie Derman

In the first quarter of 2025, sleep medicine saw a mix of regulatory shifts and promising clinical data. Although the US Food and Drug Administration (FDA) rejected the New Drug Application (NDA) for pitolisant in idiopathic hypersomnia, plans for a new registrational trial are underway. Emerging evidence also underscored the broader health impacts of poor sleep and highlighted therapeutic advances that may improve fatigue and sleep-related quality of life across diverse patient populations.

2 weeks ago | hcplive.com | Chelsie Derman

A recent study showed fertility, a history of premature birth, and treatment for allergies during pregnancy are risk factors for postpartum depression.1 “Our study underscores the comorbidity of [allergic rhinitis] and [post-partum depression], advocating for multidisciplinary collaboration among allergists, obstetricians, and midwives to provide pregnant women with expert consultation for effective [allergic rhinitis] symptom management,” wrote investigators, led by Fan Li, from the...

2 weeks ago | hcplive.com | Chelsie Derman

At the start of this week, HCPLive sat down with Steve Levine, MD, from Compass Pathways, to recap Q1 psychiatry highlights and preview Q2. Although the psychiatry pipeline may be “dry,” as Levine put it, Q1 had 5 regulatory updates from the US Food and Drug Administration (FDA) and 3 trials showcasing topline results for phase 2 and 3 trials in opioid use disorder (OUD), bipolar disorder, treatment-resistant depression, PTSD, ADHD, and schizophrenia.

3 weeks ago | hcplive.com | Chelsie Derman

The first quarter of 2025 was informative for allergists worldwide, with hundreds attending the annual American Academy of Allergy, Asthma, & Immunology (AAAAI) meeting in San Diego (February 28 – March 3). Experts discussed their latest research on peanut allergies, oral immunotherapy with autoclaved peanuts, and more. The first quarter also saw the US Food and Drug Administration (FDA) approve the first interchangeable biosimilar for omalizumab, along with newly published phase 2 and 3 data.

3 weeks ago | ajmc.com | Chelsie Derman

Both genes and environmental factors play a role in the occurrence of allergic diseases, according to a new study in Translational Pediatrics. “Our prospective study found that a family history of allergy had no effects on [atopic dermatitis], allergic rhinitis, and wheezing between the twin groups,” wrote investigators, led by Jing Wang, from the department of pediatrics at Qilu Hospital of Shandong University in China.